Our high-quality biopharmaceuticals expand treatment opportunities
Remsima is medicine for autoimmune diseases. As the world’s first antibody biosimilar trusted by pharmaceutical regulators and patients across the world, Remsima offers efficacy and safety that have been evidenced by the cumulative number of prescriptions and long-term clinical study results. Celltrion Pharm has been supplying Remsima for a reasonable price in the Korean market, thereby achieving a socioeconomic innovation that allows more patients to enjoy the benefits of the drug.
Celltrion Pharm plans to improve patients’ experience and grant more treatment options to physicians with Remsima SC, which can be administered by patients themselves. Remsima SC is the world’s first subcutaneous injection-type Infliximab, offering patients a more convenient administration option. It is expected to be a game changer in the global blockbuster pharmaceutical market.
Celltrion Pharm offers Truxima, a blood cancer medicine, and Herzuma, a breast cancer medicine, in the Korean market, thereby providing cancer patients with access to high-quality biopharmaceutical products at reasonable prices. With these high-quality products, the company proved its competitive edge by expanding its market share in the Korean anticancer biosimilar sector.
Celltrion Pharm has ventured into a new domain beyond the simple supply of biopharmaceutical products. As part of its efforts to expand its product pipelines, the company built aseptic facilities and production lines for prefilled syringe (PFS) products. After a global certification process, the company plans to produce subcutaneous injection biopharmaceuticals, including Remsima SC.